- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05284175
A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 23 subjects will be enrolled.
Experimental drug treatment: Orelabrutinib, 50mg, orally, once a day.
The subject will come to visit at week 0, 1, 2, 4, 8, 12, 16, 20, 24, 36, 48 and safety follow up visit which is planed 28 days after last administration.
Baseline patient assessment:
- Baseline examination: vital signs, physical examination, blood routine examination, urine routine examination, liver and kidney function, coagulation function, thyroid function, HIV, HCV, HBV virus test, tuberculosis test, chest X-ray, ECG and pregnancy test.
- Functional disability assessment: Expanded Disability Status Scale (EDSS) score and low contrast vision (LCVA) score.
- EQ5D scale evaluation.
- Serum AQP4-IgG titer, neuro filament light chain, T/B/NK cell count, Immunoglobulin (IgG, IgA and IgM)
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yan Xu, Doctor
- Phone Number: 18601355218
- Email: xuyanpumch@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Yan Xu, Dr.
- Phone Number: 18601355218
- Email: xuyanpumch@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1) 18-75 years old (inclusive) at the time of signing the informed consent form
- 2)Diagnosed with AQP4-IgG positive NMOSD in accordance with 2015 IPND diagnostic criteria.
- 3)Relapse ≥ 2 within 1 year before screening, and at least 1 relapse within 6 months before screening
- 4)If the subject has stable steroids treatment (≤ 7.5mg prednisone, or equivalent dose of steroids), the treatment needs to be stable more than 1 month before starting the study drug treatment.
- 5)EDSS ≤7.5 at screening
- 6)Negative pregnancy test for female of childbearing potential at screening
- 7)Understood the study procedure and voluntarily signed written informed consent
Exclusion Criteria:
- 1) History of serious heart, lung, liver, kidney, blood disease, etc.
- 2) Any major infection judged by the investigator requiring hospitalization and parenteral antimicrobial treatment within 1 month before screening
- 3) History of episodes of herpes zoster ≥ 2 or disseminated herpes zoster ≥ 1
- 4) History of or having any of the following medication / treatment: ① Received BTK inhibitor at any time in the past; ② B-cell targeted therapy within 12 weeks before the first dose; ③ Received biological agents within 12 weeks before the first dose; ④ Received live virus vaccine or live attenuated vaccine within 8 weeks before the first dose; ⑤ Received steroids treatment for other diseases within 6 months before screening, the dosage > 20mg / day for more than 21 days; ⑥ Used a study drug or other experimental treatment within 4 weeks before screening or 5 half-lives, or participating in any other intervention clinical trial.
5) During screening or baseline examination, laboratory results meet the exclusion criteria:
- Human immunodeficiency virus (HIV) positive
- Hepatitis C virus (HCV) antibody positive. (If a subject has a history of HCV infection, has completed and recorded appropriate treatment at least 1 year before screening, and the HCV RNA measured by PCR at the time of screening is negative, the subject will not be excluded from this study.)
- Hepatitis B surface antigen (HBsAg) positive and / or hepatitis B core antibody (HBcAb) positive
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2
- ALT/AST > 2 x ULN, Total Bilirubin > 1.5 x ULN, or any other clinically significant laboratory abnormality
- Neutrophil < 1500 / mm3, platelet < 75000 / mm3, lymphocyte < 1000 / mm3 or leukocyte < 3500 / mm3.
- International standardized ratio (INR) ≥ 1.5 or activated partial thromboplastin time (APTT) ≥ 1.5x ULN.
- CD19 B cells lower than the lower limit of the normal range
- 6) Used strong to medium CYP3A inducers within 3 weeks before treatment, or strong to medium CYP3A inhibitors within 1 week before treatment, or strong to medium CYP3A inducers or inhibitors may be used during treatment.
- 7) There are situations that other researchers think are not suitable to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Orelabrutinib, orally, 50 mg QD
|
Orelabrutinib, orally, 50 mg QD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized relapse rate at week 48 compared with that before baseline.
Time Frame: week 48
|
Annualized relapse rate at week 48 compared with that before baseline.
|
week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients without relapse
Time Frame: weeks 24 and 48
|
Proportion of patients without relapse at weeks 24 and 48;
|
weeks 24 and 48
|
Changes in the expanded disability status scale (EDSS) score from baseline
Time Frame: weeks 4, 12, 24, 36 and 48
|
Changes in the expanded disability status scale (EDSS) score from baseline at weeks 4, 12, 24, 36 and 48;
|
weeks 4, 12, 24, 36 and 48
|
Changes in low contrast visual acuity score (LCVA) from baseline
Time Frame: weeks 4, 12, 24, 36 and 48
|
Changes in low contrast visual acuity score (LCVA) from baseline at weeks 4, 12, 24, 36 and 48;
|
weeks 4, 12, 24, 36 and 48
|
Changes in EQ5D scores from baseline
Time Frame: weeks 12, 24, 36 and 48
|
Changes in EQ5D scores from baseline at weeks 12, 24, 36 and 48;
|
weeks 12, 24, 36 and 48
|
Changes in serum AQP4-IgG titer and neurofilament light chain protein level from baseline
Time Frame: weeks 4, 12, 24, 36 and 48
|
Changes in serum AQP4-IgG titer and neurofilament light chain protein level from baseline at weeks 4, 12, 24, 36 and 48;
|
weeks 4, 12, 24, 36 and 48
|
Changes in absolute value of peripheral blood B cell count and immunoglobulin (IgA, IgM, IgG) from baseline
Time Frame: weeks 4, 12, 24, 36 and 48
|
Changes in absolute value of peripheral blood B cell count and immunoglobulin (IgA, IgM, IgG) at weeks 4, 12, 24, 36 and 48 from baseline;
|
weeks 4, 12, 24, 36 and 48
|
Percentage of patients who withdraw from the study due to adverse events.
Time Frame: weeks1, 2, 4, 8, 12, 16, 20, 24, 36 , 48
|
Percentage of patients who withdraw from the study due to adverse events.
|
weeks1, 2, 4, 8, 12, 16, 20, 24, 36 , 48
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yan Xu, Doctor, Peking Union Medical College
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Eye Diseases
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Myelitis, Transverse
- Optic Neuritis
- Disease
- Neuromyelitis Optica
Other Study ID Numbers
- ICP-022-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromyelitis Optica Spectrum Disorder
-
Jagannadha R AvasaralaTerminatedMultiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Neuromyelitis Optica Spectrum Disorder Relapse | Neuromyelitis Optica Spectrum Disorder ProgressionUnited States
-
Tianjin Medical University General HospitalWithdrawnNeuromyelitis Optica Spectrum Disorder RelapseChina
-
Feng JinzhouNot yet recruitingNeuromyelitis Optica Spectrum Disorders
-
BiocadRecruitingNeuromyelitis Optica Spectrum DisordersRussian Federation
-
First Affiliated Hospital of Fujian Medical UniversityThird Affiliated Hospital, Sun Yat-Sen University; MyBiotech Co. Ltd, ChinaCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Tianjin Medical University General HospitalCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum DisordersChina
-
MedImmune LLCCompletedNeuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersUnited States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
-
Fu-Dong ShiCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum Disorders | Devic's DiseaseChina
-
Reistone Biopharma Company LimitedCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityNanfang Hospital of Southern Medical University; Second Affiliated Hospital... and other collaboratorsUnknownNeuromyelitis Optica Spectrum DisordersChina
Clinical Trials on Orelabrutinib
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
Ruijin HospitalRecruitingPrimary Central Nervous System LymphomaChina
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingHepatic ImpairmentChina
-
InnoCare Pharma Inc.Beijing InnoCare Pharma Tech Co., Ltd.Recruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingPrimary Immune ThrombocytopeniaChina
-
Shandong Provincial HospitalRecruitingMantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin LymphomaChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingLymphoma, Large B-Cell, Diffuse Neoplasms by Histologic TypeChina
-
Wang XinRecruiting
-
Peking University People's HospitalRecruiting